Action ImmunityBio - IBRX

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

3,4599

Prix Achat

3,45

Prix Vente

3,46

Volume échangé

6 163 033

3,08 Fourchette du Jour 3,49

2,28 Plage de 52 semaines 10,53

Cap du marché

2,411B

Clôture Veille

3,16

Ouverture

3,18

Dernière Transaction

3.4503

Dernière heure de transaction

01:18:59

Volume financier

US$ 20 499 919

VWAP

3,3263

Volume moyen (3 m)

6 058 468

Actions en circulation

696 831 296

Rendement du Dividende

Ratio Cours sur Bénéfices

-38,82

Bénéfice par action (BPA)

-0,84

Chiffre d'affairess

622k

Bénéfice net

-583,2M

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cel... ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory. Show more

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.immunitybio.com

Siège social

Wilmington, Delaware, USA

Fondé

ImmunityBio Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker IBRX. Le dernier cours de clôture d'ImmunityBio était de US$3,16. Au cours de la dernière année, les actions de ImmunityBio ont été négociées dans une fourchette de prix de US$ 2,28 à US$ 10,53.

ImmunityBio compte actuellement 696 831 296 actions en circulation. La capitalisation boursière d'ImmunityBio est de US$2,20 milliard. ImmunityBio a un ratio cours/bénéfice (ratio PE) de -38.82.

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Confirmatory trial builds on results of QUILT 3.055, a Phase 2 trial demonstrating ANKTIVA rescued T cells and activity of checkpoint inhibitors (CPIs) in patients with non-small cell lung...

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Application covers 30 countries in the European Union Submission is based on the ongoing QUILT 3.032 study in which 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle...

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.3799	12.3344155844	3.08	3.72	2.91	7590998	3.14514124	CS
4	0.8799	34.1046511628	2.58	3.72	2.28	6956335	2.89341815	CS
12	-1.9501	-36.0462107209	5.41	5.8	2.28	6058468	3.48151293	CS
26	-1.9401	-35.9277777778	5.4	7.48	2.28	5230845	4.0483109	CS
52	-0.2001	-5.46721311475	3.66	10.53	2.28	5280550	5.24916431	CS
156	-1.9801	-36.3988970588	5.44	10.53	1.21	3764910	4.29492092	CS
260	-33.0901	-90.5337893297	36.55	40.834	1.21	3184443	5.02844229	CS

IBRX - Frequently Asked Questions (FAQ)

What is the current ImmunityBio share price?

The current share price of ImmunityBio is US$ 3,4599

How many ImmunityBio shares are in issue?

ImmunityBio has 696 831 296 shares in issue

What is the market cap of ImmunityBio?

The market capitalisation of ImmunityBio is USD 2,2B

What is the 1 year trading range for ImmunityBio share price?

ImmunityBio has traded in the range of US$ 2,28 to US$ 10,53 during the past year

What is the PE ratio of ImmunityBio?

The price to earnings ratio of ImmunityBio is -38,82

What is the cash to sales ratio of ImmunityBio?

The cash to sales ratio of ImmunityBio is 36,1k

What is the reporting currency for ImmunityBio?

ImmunityBio reports financial results in USD

What is the latest annual turnover for ImmunityBio?

The latest annual turnover of ImmunityBio is USD 622k

What is the latest annual profit for ImmunityBio?

The latest annual profit of ImmunityBio is USD -583,2M

What is the registered address of ImmunityBio?

The registered address for ImmunityBio is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the ImmunityBio website address?

The website address for ImmunityBio is www.immunitybio.com

Which industry sector does ImmunityBio operate in?

ImmunityBio operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
TDTHTrident Digital Tech Holdings Ltd	US$ 1,40 (47,37%)	588,07k
CYCNCyclerion Therapeutics Inc	US$ 3,6089 (42,08%)	403,96k
KITTNauticus Robotics Inc	US$ 2,16 (38,46%)	10,57M
EVMTInvesco Electric Vehicle Matals Commodity Strategy No K 1 ETF	US$ 18,2955 (24,12%)	100
VIAVViavi Solutions Inc	US$ 11,9999 (20,12%)	341,47k
SPGCSacks Parente Golf Inc	US$ 0,8013 (-11,10%)	1,4M
FOXXFoxx Development Holdings Inc	US$ 5,74 (-10,17%)	203,85k
NAOVNanoVibronix Inc	US$ 0,53 (-10,17%)	1,01M
GITSGlobal Interactive Technologies Inc	US$ 2,37 (-10,05%)	948
SUPNSupernus Pharmaceuticals Inc	US$ 34,9007 (-9,79%)	12,19k
NVDANVIDIA Corporation	US$ 123,54 (-0,89%)	28,43M
CLEUChina Liberal Education Holdings Ltd	US$ 0,171 (15,38%)	25,12M
INTCIntel Corporation	US$ 20,7101 (3,50%)	15,86M
AAPLApple Inc	US$ 244,66 (2,98%)	11,14M
KITTNauticus Robotics Inc	US$ 2,16 (38,46%)	10,57M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

ImmunityBio Inc (IBRX)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de ImmunityBio Inc

IBRX Dernières nouvelles

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Form 4 - Statement of changes in beneficial ownership of securities

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Form 4 - Statement of changes in beneficial ownership of securities

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Form 4 - Statement of changes in beneficial ownership of securities

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Form 4 - Statement of changes in beneficial ownership of securities

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Form 424B5 - Prospectus [Rule 424(b)(5)]

IBRX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

ImmunityBio Inc (IBRX) Cours

ImmunityBio Inc (IBRX)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de ImmunityBio Inc

IBRX Dernières nouvelles

IBRX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités